Structured JSON API for this factor page: https://sharemaestro.com/factors/api/tickers/2b99c525-a76a-4b04-bbcb-e6bb713af621/
NAGE
Niagen Bioscience, Inc.Snapshot 2026-07-19 · 0.4w · Fresh
Strategy Eligibility
5 of 23 passing
★
OS Composite
✗
↗
Trending Value
✗
◆
Quality × Value
✗
🏛
Cornerstone Value
✗
🌿
Cornerstone Growth
✗
💎
Deep Value
P/E 14.0
◇
VC2 Cheapest
✗
📐
EBITDA/EV
10.8%
◐
Veiled Value
✗
▣
Piotroski Bargains
✗
🔬
Quality Compounders
ROE 23%
📈
Consistent Earners
✗
🌱
GARP
Rev +21%
🔄
Shareholder Yield
✗
💰
High Yield
✗
🚀
Momentum Leaders
✗
◉
Market Leaders
✗
◎
Tiny Titans
✗
🔍
Small Cap Value
✗
🛡
Low Volatility
✗
🏷
Sector Cheapest
✗
🧠
Capital Allocators
CAQ 0.89
⚡
Risk-Adj Momentum
✗
V
Value Analysis
Cheapness relative to fundamentals
36.0%ile
P/E
14.0×
P/S
2.0×
P/B
3.2×
E/P
0.0998
FCF Yield
0.024
EBITDA/EV
0.108
SH Yield
-0.015
Relative Strength Across Value Dimensions
Multiples & Yields — Decomposition
VC1 (5-Factor)
70.00000000
/100 — 1=cheapest
VC2 (Trending Value)
77.00000000
/100
VC3 (Buyback)
77.00000000
/100
Q
Quality Analysis
Profitability, efficiency, balance sheet & earnings quality
82.0%ile
ROE
0.226
ROA
0.163
Net Margin
0.143
Op Margin
0.151
GPA
0.733
D/E
0.39
Current
4.61
F-Score
6/9
Quality Radar — Relative Strength
Profitability & Leverage Breakdown
Rev Growth
0.208
Earn Growth
0.321
Stability
0.567
lower=better
Accruals
0.124
lower=better
5yr Consist
No
ROE of 23% is exceptional. Conservative balance sheet with D/E of 0.39. Accruals ratio of 0.124 is elevated — earnings quality may be lower than headline numbers suggest.
M
Momentum & Risk
Price trend, volatility regime, risk-adjusted returns
1.0%ile
6M Return
-47.0%
12M Return
-67.7%
12-1 Mom
-65.6%
Risk-Adj
-1.43
Vol 252d
45.9%
Vol 60d
82.7%
↑ Expanding
Max DD 12M
-67.3%
Return Comparison — 6M / 12M / 12-1
Volatility Regime — 60d vs 252d
12-1 momentum of -66% signals a downtrend — price is moving against you. Near-term vol (83%) is expanding vs long-term (46%) — risk is increasing.
OS
Composite & Factor Heatmap
All factors at a glance
0.27
Pillar Balance — Value / Quality / Momentum
Factor Heatmap — green=strong, red=weak
▦
Sector Context
Healthcare
· 500 peers
Sector Value %ile
11.8%
Sector Quality %ile
85.0%
P/E z-score
-0.25
P/B z-score
-0.17
Sector Avg OS
64.1%
Ticker vs Sector Averages
Relative Valuation Z-Score
Top Sector Peers (By OS)
Factor Interactions
Growth at Reasonable Price
Revenue growing 21% with P/E of 14×. Growth isn't fully priced in.
Earnings Quality Concern
ROE looks strong (23%) but high accruals (0.124) suggests earnings are accrual-heavy, not cash-backed.
Volatility Expanding
60-day vol (83%) significantly exceeds 252-day (46%). Near-term risk is elevated.
⚖
Factor Analysis
Comprehensive factor intelligence — strengths, weaknesses & cross-factor profile
Value
C
55.0% avg (7 factors)
Quality
B
71.1% avg (8 factors)
Momentum
F
0.0% avg (4 factors)
Risk
D
40.1% avg (1 factors)
Momentum is weak, suggesting the market isn't yet buying this thesis. Patience required. Elevated risk profile — position sizing should reflect the higher volatility.
▲ Top Strengths — highest scoring factors
▼ Key Weaknesses — lowest scoring factors
Score Trends7 snapshots
Factor Persistence7 snapshots
| Factor | Current | Streak | Trend | Spark |
|---|---|---|---|---|
| OS Composite | 0.270 | —7 | — | |
| Value %ile | 0.360 | —0 | — | |
| Quality %ile | 0.820 | —7 | — | |
| Momentum %ile | 0.010 | —7 | — | |
| F-Score | 6.000 | —0 | — | |
| Confidence | 0.940 | —7 | — | |
| Volatility | 0.459 | —7 | — |
Value Lens2021-07-20 → 2026-07-19
P/E Ratio
Earnings Yield
Value FactorsCheapness relative to fundamentals — lower multiples = cheaper
P/E Ratio
14.02
Earnings Yield (E/P)
0.0998
Price / Sales
2.00
Price / Book
3.17
Price / Cash Flow
59.01
FCF Yield
2.4%
EBITDA / EV
10.8%
Sales Yield (1/P·S)
0.6611
Shareholder Yield
Div + net buyback / mktcap
-1.5%
Quality FactorsProfitability, efficiency, and balance sheet strength
Return on Equity
22.6%
Return on Assets
16.3%
Net Margin
14.3%
Operating Margin
15.1%
Gross Profit / Assets
Novy-Marx GPA
73.3%
Debt / Equity
0.39
Current Ratio
4.61
Accruals Ratio
(NI-OCF)/Assets — lower=better
0.124
External Financing
Net issuance — lower=better
0.039
MomentumPrice trend strength over different horizons
6M Return
-47.0%
12M Return
-67.7%
12-1 Momentum
Jegadeesh-Titman (skip recent month)
-65.6%
Risk-Adjusted Momentum
Mom 12-1 ÷ Vol
-1.43
Growth & StabilityEarnings trajectory, consistency, and capital allocation
Revenue Growth (YoY)
20.8%
Earnings Growth (YoY)
32.1%
Earnings Stability (CV)
Lower = more stable
0.567
5yr Consistent
EPS up every year for 5 years
No
Piotroski F-Score
6
Buyback Yield
-1.5%
O'Shaughnessy CompositesValue Composites (WWOWS 4th Ed) — 1=cheapest, 100=most expensive
VC1 (5-factor)
P/E+P/S+P/B+P/CF+EBITDA/EV
70
VC2 (6-factor)
VC1 + Shareholder Yield — used for Trending Value
77
VC3 (6-factor)
VC1 + Buyback Yield — no dividend preference
77
Capital Allocation & AlphaAlpha within factors — quality of management decisions
Veiled Value
Expensive by P/B, cheap by everything else
No
Market Leader
Above-avg mcap+revenue, non-utility
No
All Stocks Universe
Market cap > $200M
Yes
Tiny Titan
Micro-cap, low P/S, positive momentum
No
Quarterly Fundamentals
Revenue
Net Income
FCF
Net Margin
Show all
Op Income
OCF
CapEx
Equity
Annual Fundamentals
Revenue
Net Income
FCF
Net Margin
Show all
Op Income
OCF
CapEx
Equity